BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 20, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Jan. 5, 2023

Jan. 5, 2023
Biopharmas raising money in public or private financings, including: Akamis, Bioversys, Carmot, Ensoma, Geron, Hightide, Kimia, Landos, Metagenomi, Palisade.
Read More
Bottneuro patient

Bottneuro secures $4.3M to develop its non-invasive Alzheimer’s treatment

Jan. 4, 2023
By Bernard Banga
Bottneuro AG closed the first tranche of a bridge round, bringing its total capital raise in 2022 to $4.3 million. This is being used to develop its noninvasive, domestic therapy for treating early moderate-stage Alzheimer’s patients.
Read More

Financings for Jan. 4, 2023

Jan. 4, 2023
Med-tech firms raising money in public or private financings, including: Ganymed Robotics.
Read More

Financings for Jan. 4, 2023

Jan. 4, 2023
Biopharmas raising money in public or private financings, including: Actimed, Coya, Hoth, Isa, Mantra, Sihuan.
Read More
Hong Kong stock market illustration

Cryofocus nets $27M in Hong Kong IPO for interventional cryotherapy devices

Jan. 3, 2023
By Doris Yu
Cryofocus Medtech (Shanghai) Co. Ltd. has raised HK$210 million (US$27 million) on the Hong Kong Stock Exchange. Its shares opened at HK$18.5 apiece, fell over 6% and closed at HK$17.66 on the first trading day of Dec. 30, 2022. Its shares closed at HK$16.8 per share on Jan. 3, 2023.
Read More
HKEX on phone, digital stock chart

Boan Biotech nets almost $19.6M in Hong Kong IPO

Jan. 3, 2023
By Doris Yu
Boan Biotechnology Co. Ltd. raised HK$152.8 million (US$19.6 million) from a Hong Kong IPO, capital the company will use to speed up product development, expand marketing and ramp up manufacturing.
Read More

Financings for Jan. 3, 2023

Jan. 3, 2023
Biopharmas raising money in public or private financings, including: Apnimed.
Read More
HKEX on phone, digital stock chart

Boan Biotech nets almost $19.6M in Hong Kong IPO

Dec. 30, 2022
By Doris Yu
Boan Biotechnology Co. Ltd. raised HK$152.8 million (US$19.6 million) from a Hong Kong IPO, capital the company will use to speed up product development, expand marketing and ramp up manufacturing.
Read More

Financings for Dec. 30, 2022

Dec. 30, 2022
Biopharmas raising money in public or private financings, including: Cyclo, GT, Hoth, Palisade, Unicycive.
Read More

Numares gets $21.2M to develop a new MRS-based diagnostic platform

Dec. 29, 2022
By Bernard Banga
Numares Health AG received $21.2 million from the European Investment Bank (EIB) in support to its automated and software based IVD platform for obtaining high-quality nuclear magnetic resonance metabolomics data from blood or urine biopsy samples.
Read More
Previous 1 2 … 317 318 319 320 321 322 323 324 325 … 673 674 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • Skin through magnifier

    Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis

    BioWorld
    Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing